Request Demo
Last update 08 Mar 2025
Hangzhou Converd Co., Ltd.
Last update 08 Mar 2025
Overview
Tags
Neoplasms
Infectious Diseases
Skin and Musculoskeletal Diseases
Oncolytic virus
Small molecule drug
Synthetic peptide
Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Related
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
CTR20231668
评价重组人IL-21溶瘤痘病毒注射液（hV01）治疗对标准治疗无效或失败的晚期恶性实体瘤的安全性、耐受性、药代动力学特征和生物学作用的剂量递增I期临床研究。
[Translation] A dose-escalation Phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and biological effects of recombinant human IL-21 oncolytic poxvirus injection (hV01) in the treatment of advanced malignant solid tumors that are ineffective or have failed standard treatment.
NCT05914376
A Phase I Dose Escalation Study to Evaluate the Safety, Tolerance, Pharmacokinetics, and Biological Properties of Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Patients With Advanced Malignant Solid Tumors
CTR20191802
评价KX02片口服给药在晚期实体瘤患者中安全性、耐受性及药代动力学和初步有效性的I期临床研究
[Translation] A Phase I clinical study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of oral KX02 tablets in patients with advanced solid tumors
100 Clinical Results associated with Hangzhou Converd Co., Ltd.
Login to view more data
Login to view more data
100 Deals associated with Hangzhou Converd Co., Ltd.
Login to view more data
100 Translational Medicine associated with Hangzhou Converd Co., Ltd.
Login to view more data
Corporation Tree
Boost your research with our corporation tree data.
login
or
Pipeline
Pipeline Snapshot as of 04 Apr 2025
The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Preclinical
3
1
IND Application
Phase 1
1
1
Phase 2
Other
2
Login to view more data
Current Projects
Login to view more data
Deal
Boost your decision using our deal data.
login
or
Translational Medicine
Boost your research with our translational medicine data.
login
or
Profit
Explore the financial positions of over 360K organizations with Synapse.
login
or
Grant & Funding(NIH)
Access more than 2 million grant and funding information to elevate your research journey.
login
or
Investment
Gain insights on the latest company investments from start-ups to established corporations.
login
or
Financing
Unearth financing trends to validate and advance investment opportunities.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free